Market research
S1BA.F Stealth BioTherapeutics Corp
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 23M
- P/E ratio
- Not available
- Analyst target
- 3.25
- Dividend yield
- 0.0%
- Beta
- 1.46
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 23M
- P/E ratio
- Not available
- Analyst target
- 3.25
- Dividend yield
- 0.0%
- Beta
- 1.46
About
About Stealth BioTherapeutics Corp
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands. As of November 16, 2022, Stealth BioTherapeutics Corp was taken private.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the S1BA.F discussion.
5 years, 5 months ago
Stealth BioTherapeutics Corp is currently in a long term downtrend where the price is trading 0.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
Stealth BioTherapeutics Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 32.2% to $-11M since the same quarter in the previous year.
Based on the above factors, Stealth BioTherapeutics Corp gets an overall score of 2/5.